GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RegeneRx Biopharmaceuticals RGRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

$76,761

FY2014FY2022

Net income

−$1.7m

FY2014FY2022

Free cash flow

−$940,718

FY2014FY2022

Shareholders' equity

−$3.4m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$76,761$76,761$76,761$76,762$69,667$56,652$93,308$60,612—
Gross profit———$76,762−$11,376−$87,259−$144,036−$142,573−$367,275
Research and development—$6,638$4,921$65,107$81,043$143,911$237,344$203,000$367,000
Operating income−$1.4m−$1.3m−$1.3m−$1.3m−$1.3m−$1.4m−$1.7m−$1.7m−$1.6m
Net income−$1.7m−$1.6m−$1.5m−$1.4m−$2.0m$286,487$229,125−$5.3m−$2.8m
Diluted earnings per share-1.20-0.01-0.01-0.01-0.020.000.00-0.05-0.03

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$382,177$1.3m$551,788$711,760$281,040$227,073$862,402$358,223$949,000
Total liabilities$3.8m$3.5m$3.4m$3.1m$2.5m$4.3m$6.9m$7.1m$2.7m
Debt$1.4m$1.1m$923,775$708,070$54,754$634,855$812,022$1.4m$1.1m
Shareholders' equity−$3.4m−$2.2m−$2.8m−$2.3m−$2.2m−$4.1m−$6.1m−$6.7m−$1.7m
Shares outstanding1m144m133m132m128m110m126m102m93m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$940,718−$990,296−$1.0m−$1.1m−$888,294−$663,085−$1.1m−$525,340−$1.7m
Capital spending———————−$1,076−$13,000
Free cash flow−$940,718−$990,296−$1.0m−$1.1m−$888,294−$663,085−$1.1m−$526,416−$1.7m

Latest quarters

By quarter end

Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021
Revenue$19,190$19,190$19,190$19,191$19,191$19,190$19,190$19,191
Operating income−$304,912−$308,845−$284,463−$464,842−$343,841−$367,602−$404,046−$257,447
Net income−$385,200−$390,906−$366,508−$545,976−$424,065−$449,585−$429,845−$338,633
Diluted earnings per share-0.27-0.27-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$186,810$382,177$580,987$735,504$960,527$1.3m$1.6m$2.1m
Debt$262,015$1.4m$1.3m$1.3m$1.2m$1.1m$1.1m$1.0m
Shareholders' equity−$3.7m−$3.4m−$3.1m−$2.9m−$2.6m−$2.2m−$1.9m−$1.6m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.0%6.3%-24.9%
Operating income3.6%-0.6%—
Net income7.1%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1778.6%-1721.9%-1858.7%—
Net margin-2166.0%-2036.5%-1836.8%—

Valuation history

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2015FY2014FY2013FY2012
Price to earnings-1.5-189.8-203.4-68.4-28.9188.3-24.5-14.1——
Price to sales34.3———————7.70.3

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-100%7230%-100%-7%-17%228%166%-41%-49%-27%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 18 Oct 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.